LivaNova PLC (LIVN) Given Average Rating of “Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has been assigned an average rating of “Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $79.14.

Several brokerages have commented on LIVN. Needham & Company LLC increased their price target on shares of LivaNova to $93.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. Canaccord Genuity reiterated a “hold” rating and issued a $76.00 price target on shares of LivaNova in a research note on Tuesday, November 14th. Zacks Investment Research upgraded shares of LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price target on the stock in a research note on Thursday, November 9th. BTIG Research reiterated a “hold” rating on shares of LivaNova in a research note on Tuesday, November 7th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $85.00 price target on shares of LivaNova in a research note on Friday, November 3rd.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $74.58, for a total value of $74,580.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Alfred J. Novak sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Insiders sold 6,830 shares of company stock valued at $557,100 over the last three months. Corporate insiders own 0.28% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in shares of LivaNova by 9.8% during the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after purchasing an additional 153 shares during the period. Texas Permanent School Fund lifted its holdings in shares of LivaNova by 0.8% during the second quarter. Texas Permanent School Fund now owns 31,658 shares of the company’s stock worth $1,938,000 after purchasing an additional 265 shares during the period. Arizona State Retirement System lifted its holdings in shares of LivaNova by 1.7% during the second quarter. Arizona State Retirement System now owns 18,300 shares of the company’s stock worth $1,120,000 after purchasing an additional 300 shares during the period. State Treasurer State of Michigan lifted its holdings in shares of LivaNova by 1.7% during the second quarter. State Treasurer State of Michigan now owns 17,900 shares of the company’s stock worth $1,096,000 after purchasing an additional 300 shares during the period. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of LivaNova by 3.7% during the second quarter. Louisiana State Employees Retirement System now owns 11,300 shares of the company’s stock worth $692,000 after purchasing an additional 400 shares during the period. 86.07% of the stock is owned by institutional investors and hedge funds.

LivaNova (LIVN) traded down $0.80 during mid-day trading on Friday, hitting $87.18. 539,800 shares of the company were exchanged, compared to its average volume of 390,271. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. LivaNova has a 12-month low of $44.21 and a 12-month high of $88.43. The stock has a market capitalization of $4,200.00 and a price-to-earnings ratio of 25.42.

LivaNova (NASDAQ:LIVN) last released its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 earnings per share. sell-side analysts forecast that LivaNova will post 3.33 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “LivaNova PLC (LIVN) Given Average Rating of “Buy” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/01/livanova-plc-livn-given-average-rating-of-buy-by-brokerages.html.

About LivaNova

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply